Acadian Asset Management
AERI

Acadian Asset Management’s Aerie Pharmaceuticals AERI Stock Holding History

Acadian Asset Management’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-80,402
Closed -$603K – 1919
2022
Q2 		$603K Buy
+80,402
New +$567K ﹤0.01% 927
2021
Q3 		– Sell
-3,131
Closed -$50K – 2112
2021
Q2 		$50K Buy
+3,131
New +$53.7K ﹤0.01% 1801

Other funds holding AERI

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acadian Asset Management's AERI Position: Q3 2022 in Review

Acadian Asset Management sold out of Aerie Pharmaceuticals (AERI) in Q3 2022, closing a stake of 80,402 shares — an estimated $603K sold.

Acadian Asset Management first reported a position in AERI in Q2 2021 and held it in 2 quarters. The position peaked at $603K in Q2 2022. 156 funds tracked by Wall St. Rank hold AERI as of Q3 2022.

  • Acadian Asset Management reported no remaining Aerie Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Acadian Asset Management sold 80,402 Aerie Pharmaceuticals shares in Q3 2022, an estimated $603K.
  • Acadian Asset Management first reported a position in Aerie Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • Acadian Asset Management's Aerie Pharmaceuticals position peaked at $603K in Q2 2022.
  • 156 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2022.

Based on Acadian Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.